Ashland Global Holdings Inc. has launched collapeptyl, a new biofunctional innovation in collagen science designed to meet consumer demands for sustainable, multifunctional skincare ingredients. This vegan-suitable, non-PFAS, and 99.7% natural solution utilizes Ashland's patent-pending 2HP technology (Hyaluronic Hybrid Peptide).
Clinical studies demonstrate impressive efficacy, including a synergistic increase of collagen I by 44% and hyaluronic acid by 57% in ex vivo skin. Collapeptyl also corrects the appearance of expression wrinkles in just four hours and reduces deep wrinkle circumference by 196% and depth by 105% after one month.
The product addresses key market trends such as K-beauty influence, clean beauty, sustainability, and multifunctionality, offering both immediate sensorial benefits and long-term biological effects. This launch further boosts Ashland's technology-rich biofunctionals offering and globalization strategy in the personal care market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.